No Data
Mabpharm Limited (HKG:2181) Adds HK$392m in Market Cap and Insiders Have a 50% Stake in That Gain
MABPHARM-B: 2024 Interim Report
Express News | Mabpharm H1 Revenue RMB 108.5 Million
MABPHARM-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
MeiBo Pharmaceutical Group-B (02181.HK) plans to hold a board of directors meeting on August 28th to approve the mid-term performance.
On August 15th, Glowanews reported that Meaboyao-B (02181.HK) announced that the board of directors meeting will be held on Wednesday, August 28, 2024 to consider and approve the mid-term performance of the company and its subsidiaries, up to June 30, 2024, as well as to handle any other matters that may arise.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Some Mabpharm Limited (HKG:2181) Shareholders Look For Exit As Shares Take 41% PoundingNo Data
No Data
